These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 6572561

  • 1. Development of a cell kinetic approach to curative therapy of acute myelocytic leukemia in remission using the cell cycle-specific drug 1-beta-D-arabinofuranosylcytosine in a rat model.
    Vaughan WP, Burke PJ.
    Cancer Res; 1983 May; 43(5):2005-9. PubMed ID: 6572561
    [Abstract] [Full Text] [Related]

  • 2. Drug induced host factors which stimulate growth of residual leukemia in Lewis x Brown Norway F1 (LEW-BN) rats.
    Burke PJ, Karp JE, Saylor PL.
    Cancer Res; 1986 Apr; 46(4 Pt 1):1813-6. PubMed ID: 3485014
    [Abstract] [Full Text] [Related]

  • 3. Effect of the interval between high dose 1-beta-D-arabinofuranosylcytosine injections on leukemic cell load, intestinal toxicity, and normal hematopoietic stem cells in a rat model for acute myelogenous leukemia.
    Colly LP, Peters WG, Willemze R.
    Cancer Res; 1986 Aug; 46(8):3825-7. PubMed ID: 3460691
    [Abstract] [Full Text] [Related]

  • 4. Chemotherapy of leukemia in mice, rats, and humans relating time of humoral stimulation, tumor growth, and clinical response.
    Burke PJ, Karp JE, Vaughan WP.
    J Natl Cancer Inst; 1981 Sep; 67(3):529-38. PubMed ID: 6944525
    [Abstract] [Full Text] [Related]

  • 5. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP, Preisler HD, Slocum H, Rustum YM.
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [Abstract] [Full Text] [Related]

  • 6. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R, Guardia R, Altés A, Sureda A, Brunet S, Sierra J.
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [Abstract] [Full Text] [Related]

  • 7. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
    Cragg LH, Andreeff M, Feldman E, Roberts J, Murgo A, Winning M, Tombes MB, Roboz G, Kramer L, Grant S.
    Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
    [Abstract] [Full Text] [Related]

  • 8. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
    Blumenreich MS, Chou TC, Andreeff M, Vale K, Clarkson BD, Young CW.
    Cancer Res; 1984 Feb; 44(2):825-30. PubMed ID: 6692380
    [Abstract] [Full Text] [Related]

  • 9. Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia.
    Schwartz SA, Morgenstern B, Capizzi RL.
    Cancer Res; 1982 Jun; 42(6):2191-7. PubMed ID: 7074600
    [Abstract] [Full Text] [Related]

  • 10. Modulation of 1-beta-D-arabinofuranosylcytosine metabolism by thymidine in human acute leukemia.
    Zittoun R, Zittoun J, Marquet J, Rustum Y, Creaven P.
    Cancer Res; 1985 Oct; 45(10):5186-92. PubMed ID: 4027995
    [Abstract] [Full Text] [Related]

  • 11. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
    Karp JE, Passaniti A, Gojo I, Kaufmann S, Bible K, Garimella TS, Greer J, Briel J, Smith BD, Gore SD, Tidwell ML, Ross DD, Wright JJ, Colevas AD, Bauer KS.
    Clin Cancer Res; 2005 Dec 01; 11(23):8403-12. PubMed ID: 16322302
    [Abstract] [Full Text] [Related]

  • 12. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
    Rodríguez JN, Fernández-Jurado A, Martino ML, Diéguez JC, Moreno MV, Quesada JA, Polo B, Cañavate M, Amian A, Prados D.
    Sangre (Barc); 1998 Feb 01; 43(1):35-9. PubMed ID: 9580427
    [Abstract] [Full Text] [Related]

  • 13. Close reproduction by different laboratories of characteristics of circadian rhythm in 1-beta-D-arabinofuranosylcytosine tolerance by mice.
    Scheving LE, Haus E, Kühl JF, Pauly JE, Halberg F, Cardoso S.
    Cancer Res; 1976 Mar 01; 36(3):1133-7. PubMed ID: 1253172
    [Abstract] [Full Text] [Related]

  • 14. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V, Estey E, Du M, Keating MJ, Plunkett W.
    Clin Cancer Res; 1997 Sep 01; 3(9):1539-45. PubMed ID: 9815841
    [Abstract] [Full Text] [Related]

  • 15. Survival and cure of leukemic mice after circadian optimization of treatment with cyclophosphamide and 1-beta-D-arabinofuranosylcytosine.
    Scheving LE, Burns ER, Pauly JE, Halberg F, Haus E.
    Cancer Res; 1977 Oct 01; 37(10):3648-55. PubMed ID: 908013
    [Abstract] [Full Text] [Related]

  • 16. Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial.
    Karp JE, Ross DD, Yang W, Tidwell ML, Wei Y, Greer J, Mann DL, Nakanishi T, Wright JJ, Colevas AD.
    Clin Cancer Res; 2003 Jan 01; 9(1):307-15. PubMed ID: 12538483
    [Abstract] [Full Text] [Related]

  • 17. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
    Beran M, Jeha S, O'Brien S, Estey E, Vitek L, Zurlo MG, Rios MB, Keating M, Kantarjian H.
    Clin Cancer Res; 1997 Dec 01; 3(12 Pt 1):2377-84. PubMed ID: 9815637
    [Abstract] [Full Text] [Related]

  • 18. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
    Giles F, Verstovsek S, Thomas D, Gerson S, Cortes J, Faderl S, Ferrajoli A, Ravandi F, Kornblau S, Garcia-Manero G, Jabbour E, O'Brien S, Karsten V, Cahill A, Yee K, Albitar M, Sznol M, Kantarjian H.
    Clin Cancer Res; 2005 Nov 01; 11(21):7817-24. PubMed ID: 16278404
    [Abstract] [Full Text] [Related]

  • 19. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY, Yang LJ, Xu B, Liu XL, Zheng WY, Zhang Y, Huang F, Sun J, Liu QF.
    Ai Zheng; 2003 Dec 01; 22(12):1330-3. PubMed ID: 14693062
    [Abstract] [Full Text] [Related]

  • 20. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
    Hołowiecki J, Grosicki S, Kyrcz-Krzemien S, Skotnicki AB, Piatkowska-Jakubas B, Warzocha K, Seferynska I, Zdziarska B.
    Ann Hematol; 2008 May 01; 87(5):361-7. PubMed ID: 18074133
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.